FDA approves Roche’s Susvimo for DME

The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic macular edema (DME), said Swiss pharma giant Roche (ROG: SIX).

Roche noted that Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to US retina specialists and their patients with DME.

Affecting around 29 million people globally, DME is a vision-threatening retinal condition associated with blindness and decreased quality of life when left untreated.